Comparing two doses of rivaroxaban for leg vein clots
Part of Heart & circulation clinical trials.
This trial tests if a full dose of rivaroxaban (a blood thinner) works better than a lower preventive dose for treating a superficial vein clot in the leg. It aims to find the safest and most effective way to stop the clot from getting worse or causing a more serious clot.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosed superficial vein clot in your leg that the doctor found within the last 14 days.
- You cannot be already taking a blood thinner for another reason (like a heart condition).
- You cannot have had a serious blood clot (DVT or PE) in the last 6 months or any major bleeding in the last month.
- You must not have severe kidney or liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.
This study tests a low-dose blood thinner called rivaroxaban, given for 90 days after a recent ischemic stroke, to see if it reduces the risk of another stroke or heart problems. It may be an option for people who are already receiving standard stroke care and are not on full-dose blood thinners.
This trial compares two medicines to prevent blood clots after heart valve surgery. If you've had a tissue valve replaced or repaired, this study will see if a newer blood thinner (rivaroxaban) is safer and works better than the standard treatment.
This trial tests whether a lower dose of the blood thinner rivaroxaban works as well as the standard dose for people 70 and older with atrial fibrillation (an irregular heartbeat). The goal is to find the safest dose to prevent strokes while reducing bleeding risks.
This trial compares close monitoring (“watch and wait”) versus taking the blood thinner rivaroxaban in people with a small type of lung blood clot. It aims to find out whether low-risk patients can safely avoid or reduce anticoagulation while still staying healthy.
This study tests a blood thinner (rivaroxaban) versus usual care to see if it can prevent strokes in older adults with extra heartbeats (a sign of possible heart rhythm problems) and high stroke risk. If you qualify, the treatment might reduce your chances of having a stroke.
Hear when a new Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.